The overnight sleep lab, wired and uncomfortable, told you about a single night. Wesper turned it into a thin wireless patch you wear at home - and gave doctors clinical-grade data they can trust.
Most people who have sleep apnea never find out. Not because they don't care - because the standard test is a wall. You wire yourself to a machine, thread a tube up your nose, and spend one unfamiliar night in a clinic. Then you get results for that one night. Wesper, a New York company founded in 2017, was built on a plainer question: what if the test happened in your own bed?
Wesper makes an FDA-cleared, at-home sleep-testing system. Two thin, flexible, single-use patches sit on the chest and abdomen. Paired with a phone app and a pulse oximeter, they measure sleep position, respiratory effort, airflow and blood-oxygen levels through the night, streaming data over Bluetooth to the cloud where a physician can review it.
The company grew out of hard science. Before founding Wesper - originally named Tatch - CEO Dr. Amir Reuveny earned a PhD in electrical engineering from the University of Tokyo, pioneering ultraflexible electronics, and worked as a postdoctoral fellow at Cornell Tech studying commercial applications for flexible circuits. Co-founder Adi Mordechai leads the technology side.
What Wesper sells, in the end, is not just a patch. It is a workflow: a comfortable test patients will actually complete, plus a provider portal that folds the physician's review into the product. Comfort, in diagnostics, is not a luxury. It is often the difference between a test that gets finished and one that never happens.
*Company-reported correlation with traditional in-lab polysomnography. Funding figures are approximate and drawn from public reporting.
Wesper's key design move: it computes airflow from thoracoabdominal movement instead of a tube in your face - and it can be worn again and again to capture how sleep really behaves.
Two flexible, single-use patches go on the chest and abdomen. Thin, wireless, disposable.
Sensors capture position, respiratory effort, airflow and SpO2 using accelerometry and optical sensing.
Data flows over Bluetooth Low Energy to the app all night, then uploads for analysis.
A clinician reviews high-resolution results in the provider portal to help identify obstructive sleep apnea.
Wesper empowers healthcare providers with reliable, high-resolution data to improve sleep health, streamline workflows, and enhance outcomes.
The home sleep testing system: two wireless patches, a mobile app and a paired pulse oximeter for diagnosing obstructive sleep apnea in adults - at home or in a clinic.
Single-use flexible patches built on printed electronics, using accelerometry and optical sensing, transmitting over Bluetooth Low Energy through the night.
A clinician portal and data-analysis layer for reviewing high-resolution results, managing patients and interpreting longitudinal trends to improve clinic efficiency.
A tiered suite of diagnostic options for personalized sleep care, unveiled at the annual meeting of the Associated Professional Sleep Societies.
Wesper sits between two audiences. Sleep physicians and clinics order and interpret the tests through the provider portal; patients complete the testing at home. That B2B2C shape lets Wesper improve the clinician's workflow while making the patient's experience dramatically easier. Distribution reaches consumers directly, including through retail channels like cpap.com.
Sleep apnea is linked to heart disease, stroke, diabetes and daytime accidents, yet most cases go undiagnosed because the diagnostic path is uncomfortable and inconvenient. And a single lab night is a snapshot - sleep changes with stress, weight, alcohol and position. Wesper lowers the barrier to testing and supports repeat, longitudinal measurement, so the picture reflects how someone actually sleeps.
Traditional home sleep tests and in-lab studies rely on wires and a nasal cannula. Wesper removes the cannula by reading breathing from body movement, and it is designed for repeat use rather than a one-night snapshot. Against competitors like WatchPAT, ResMed's home testing, Onera Health and NightOwl, Wesper's wedge is the combination of a comfortable wearable, clinical-grade correlation, and a connected provider workflow.
The strategic logic: own the comfortable, at-home test first, then expand up and down the severity ladder. That is exactly what the multi-tier ecosystem unveiled at SLEEP 2026 signals - different levels of testing for different patients, all on one platform. Start with the wedge nobody else wants, then grow into the whole staircase.
Wesper's $9.6M Series A (November 2022) drew investors who like large, workflow-stuck markets - Valor Equity Partners, Breyer Capital and Spark Capital, alongside health-tech angels.
Reported figures vary across public sources (Series A cited as $7.5M–$9.6M; total raised reported between roughly $16M and $24M). Treat as approximate.
Amir Reuveny and Adi Mordechai start the company in New York to reinvent sleep testing with flexible electronics.
Wesper Lab receives FDA 510(k) clearance (K221816) as a wireless patch home sleep test for obstructive sleep apnea.
A Series A led by health-focused investors including Valor Equity Partners, Breyer Capital and Spark Capital.
Wesper publicly frames its technology as a comfortable, FDA-cleared replacement for traditional testing.
At SLEEP 2026, Wesper unveils its first multi-tier sleep diagnostic ecosystem for personalized care.
Wesper provides FDA-cleared, at-home sleep apnea testing using thin wireless patches, a mobile app, and a cloud provider portal that gives physicians clinical-grade sleep data.
Two single-use flexible patches on the chest and abdomen measure sleep position, respiratory effort and airflow using accelerometry and optical sensing, streaming data via Bluetooth to the app and cloud; a paired pulse oximeter adds pulse rate and oxygen saturation.
Yes. Wesper Lab received FDA 510(k) clearance (K221816) in 2022 to assist trained personnel in diagnosing obstructive sleep apnea in adults.
Wesper was founded in 2017 - originally named Tatch - by Dr. Amir Reuveny, its CEO, and Adi Mordechai, in New York City.
Wesper lets patients test at home without wires or a nasal cannula and supports repeat, longitudinal testing, while reporting close correlation to in-lab polysomnography.
Sources: wesper.co · FDA 510(k) K221816 · PRNewswire · Sleep Review · AASM · Crunchbase / Tracxn. Figures approximate where noted.